Thomas M. Fitzgerald
Mr. Fitzgerald was named CEO of CellTraffix Inc. (then StemCapture Inc.) in 2007 and was elected to the Board of Directors in 2008. He has led the strategic re-positioning, formed the management team, and developed the commercialization strategy for the CellTraffix business. Mr. Fitzgerald has more than 25 years of experience in the biopharmaceutical industry. In recent years as a strategic consultant with a select group of clients, he has provided strategic direction, raised capital, and provided management for a range of early stage life science companies, as well as provided counsel and guidance to more established domestic and international businesses and their investors. He has also advised the University of Rochester Medical Center on their initiative to generate and nurture spin-out businesses in the life sciences.
A lawyer by training, for the past 15 years Mr. Fitzgerald’s responsibilities have been substantially in the identification of commercial opportunities as well as the development and commercialization of products. He has extensive transactional experience including the acquisition and disposal of products and business units, structuring of strategic alliances, providing intellectual property risk assessment and protection, developing regulatory strategy, and overseeing the clinical development of pharmaceuticals and delivery systems for therapeutics, as well as handling day to day business operations for a number of companies.
Mr. Fitzgerald has held seats on the Boards of Directors for a number of public and private entities. During his career, he has been responsible for the development, regulatory and marketing strategies, government relations, and intellectual property matters for biopharmaceutical companies. He is a frequent panelist and speaker at industry and financial seminars and conferences.
Besides his work with CellTraffix, Mr. Fitzgerald has served as Interim CEO of OyaGen Inc. and Managing Director of Socratech LLC. He is also affiliated with CAM-Global and Colonial Technology Development Co. consulting firms on life science business opportunities. He was Chief Executive Officer and Chief Operating Officer with Sheffield Pharmaceuticals Inc. (now MAP Pharma) and Senior Vice President and General Counsel & Secretary at Fisons Corp (now Sanofi Aventis). In addition, Mr. Fitzgerald has held senior management positions with SmithKlineBeecham (now GlaxoSmithKline).
Mr. Fitzgerald is a graduate of Boston College and the St. John’s University School of Law and is admitted to practice law in New York and Connecticut State and Federal Courts. He was awarded the distinguished Alumni Medal from St. John’s University, Jamaica, NY.
Stuart G. MacDonald
Vice President of Research and Development
Joined CellTraffix in 2008. He is experienced in research and development with a broad engineering and science background, emphasizing a systems approach to developing complex technology. Most recently he was Vice-President of Research and Development at Biophan Inc. Mr. MacDonald held a series of senior management positions with Ortho-Clinical Diagnostics, a Johnson & Johnson company, where he was a Vice President responsible for overall management of the Instrumentation R&D group. Previously he worked at Eastman Kodak Company as Assistant Director, Clinical Diagnostic Research Labs. Mr. MacDonald has B.S. and Masters of Engineering degrees in Mechanical Engineering from Cornell University. He is licensed as a Professional Engineer by the State of New York, and currently holds 40 US Patents.
Paul M. LeFrois, Jr.
Director of Finance
Mr. LeFrois became Director of Finance of CellTraffix Inc. in August of 2007 after having served as Controller since January 2006. He also serves as CFO for Biomed Solutions LLC, Technology Innovations LLC, and Controller for NaturalNano Inc. From 2003 to 2005, he was the Vice President of Finance and Administration of Complemar Partners Inc., a fulfillment provider in Rochester, New York. From 2002 to 2003, Mr. LeFrois served as financial analyst assigned to mergers and acquisitions for Lightnin’, an SPX Company; a worldwide mixing and processing manufacturer located in Rochester, New York. From 1995-2002, he served in various areas of progressing responsibility, culminating in Director of Operations for Vanteon Corporation, a computer programming services company in Rochester, New York. Mr. LeFrois holds a Bachelor of Business Administration degree from St. Bonaventure University.
After receiving his Ph.D. in Biophysics from the University of Rochester in 2005, Dr. Strohsahl and a group of colleagues founded Lighthouse Biosciences, Inc., a start-up focused on commercializing the olignucleotide-based diagnostic arrays he had a developed as a graduate student. At Celltraffix, he will now apply his expertise of both biological interactions at a liquid-surface interface and the transition of a technology from a bench science to market-ready product in order to guide the optimization of the company's technology.
Dr. Strohsahl is a classically trained biophysicist with expertise in the fields of biotechnology, nanotechnology, organic chemistry and molecular biology. Strohsahl's specific expertise centers on device development and assay design, olignucleotide modeling, DNA surface chemistry, PCR assay development and several aspects of clinical sample preparation. As a result of his professional pursuits, he has also gained signifigant experience in small business development and management, including the determination of market needs and freedom to operate through extensive literature and patent searches and the preparation of patent applications and SBIR/STTR grant proposals.